Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.

Szczegóły
Abstrakt

Tytuł:: Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.
Autorzy:: González-Martínez S; Clinical Researcher, Hospital Ramón y Cajal, 28034 Madrid, Spain.
Pérez-Mies B; Department of Pathology, Hospital Ramón y Cajal, 28034 Madrid, Spain.; Institute Ramón y Cajal for Health Research (IRYCIS), 28034 Madrid, Spain.; CIBER-ONC, Instituto de Salud Carlos III, 28029 Madrid, Spain.; Faculty of Medicine, University of Alcalá de Henares, Alcalá de Henares, 28801 Madrid, Spain.
Pizarro D; Institute Ramón y Cajal for Health Research (IRYCIS), 28034 Madrid, Spain.
Caniego-Casas T; Institute Ramón y Cajal for Health Research (IRYCIS), 28034 Madrid, Spain.
Cortés J; CIBER-ONC, Instituto de Salud Carlos III, 28029 Madrid, Spain.; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, 28670 Madrid, Spain.; International Breast Cancer Center (IBCC), Quironsalud Group, 08017 Barcelona, Spain.; Medica Scientia Innovation Research, 08007 Barcelona, Spain.; Medica Scientia Innovation Research, Ridgewood, NJ 07450, USA.; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
Palacios J; Department of Pathology, Hospital Ramón y Cajal, 28034 Madrid, Spain.; Institute Ramón y Cajal for Health Research (IRYCIS), 28034 Madrid, Spain.; CIBER-ONC, Instituto de Salud Carlos III, 28029 Madrid, Spain.; Faculty of Medicine, University of Alcalá de Henares, Alcalá de Henares, 28801 Madrid, Spain.
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Jul 09; Vol. 22 (14). Date of Electronic Publication: 2021 Jul 09.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:: B7-H1 Antigen/*metabolism
Breast Neoplasms/*drug therapy
Breast Neoplasms/*immunology
Carcinoma/*immunology
Carcinoma/*metabolism
Epithelial-Mesenchymal Transition/*immunology
B7-H1 Antigen/immunology ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/immunology ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Cadherins/metabolism ; Carcinoma/drug therapy ; Carcinoma/genetics ; Epithelial-Mesenchymal Transition/drug effects ; Epithelial-Mesenchymal Transition/genetics ; Female ; Humans ; Lymphocytes, Tumor-Infiltrating/immunology ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/immunology ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology
References:: Mol Cancer Res. 2012 Mar;10(3):293-304. (PMID: 22267545)
Nat Cell Biol. 2008 Mar;10(3):295-305. (PMID: 18297062)
Oncoimmunology. 2018 Feb 15;7(4):e1345415. (PMID: 29632713)
NPJ Breast Cancer. 2017 Mar 29;3:8. (PMID: 28649648)
Ann Surg Oncol. 2018 Aug;25(8):2249-2260. (PMID: 29855830)
Clin Breast Cancer. 2020 Aug;20(4):326-331.e1. (PMID: 32197944)
Breast Cancer Res. 2020 Aug 18;22(1):92. (PMID: 32811533)
Cancers (Basel). 2020 Jul 08;12(7):. (PMID: 32650408)
Cell. 2008 May 16;133(4):704-15. (PMID: 18485877)
Breast Cancer Res Treat. 2010 Apr;120(3):627-37. (PMID: 20143153)
Cancer Res. 1999 Feb 15;59(4):947-52. (PMID: 10029089)
Oncogene. 2007 Dec 13;26(57):7859-71. (PMID: 17603561)
Nat Cell Biol. 2006 Dec;8(12):1398-406. (PMID: 17072303)
Ann Surg Oncol. 2011 Jan;18(1):94-103. (PMID: 20585866)
Breast Cancer Res Treat. 2011 Apr;126(2):471-8. (PMID: 21287362)
Nat Rev Cancer. 2007 Jun;7(6):415-28. (PMID: 17508028)
Clin Breast Cancer. 2017 Aug;17(5):382-391. (PMID: 28529029)
BMC Cancer. 2009 Sep 14;9:325. (PMID: 19751508)
Breast. 2013 Oct;22(5):968-73. (PMID: 23787124)
Nature. 2007 Apr 19;446(7138):882-7. (PMID: 17392792)
Eur J Cell Biol. 2014 Oct;93(10-12):438-44. (PMID: 25113547)
Prog Mol Biol Transl Sci. 2013;116:71-94. (PMID: 23481191)
Oncogene. 2010 Jun 17;29(24):3490-500. (PMID: 20418909)
EMBO J. 2003 May 15;22(10):2443-52. (PMID: 12743038)
Breast Cancer Res Treat. 2015 Feb;150(1):31-41. (PMID: 25677743)
PLoS One. 2015 Jun 26;10(6):e0131409. (PMID: 26115045)
Mol Cell. 2001 Jun;7(6):1267-78. (PMID: 11430829)
J Clin Invest. 2009 Jun;119(6):1420-8. (PMID: 19487818)
Am J Surg. 2006 May;191(5):657-64. (PMID: 16647355)
Cancer Res. 2008 Feb 15;68(4):989-97. (PMID: 18281472)
Clin Breast Cancer. 2017 Feb;17(1):e1-e10. (PMID: 27568101)
Cancer Cell. 2009 May 5;15(5):416-28. (PMID: 19411070)
Endocr Relat Cancer. 2015 Jun;22(3):443-54. (PMID: 25870251)
Nat Rev Cancer. 2014 Feb;14(2):121-34. (PMID: 24442140)
World J Surg Oncol. 2013 Jun 06;11:129. (PMID: 23738706)
Breast Cancer Res. 2010;12(2):201. (PMID: 20346098)
Ann Oncol. 2015 Jul;26(7):1346-52. (PMID: 25878190)
Ann Oncol. 2006 Apr;17(4):605-13. (PMID: 16469754)
Br J Cancer. 1994 Jan;69(1):157-62. (PMID: 8286199)
Breast Cancer Res Treat. 2007 Mar;101(3):349-53. (PMID: 17009109)
J Clin Oncol. 2020 Feb 10;38(5):388-394. (PMID: 31461380)
Mol Cancer Res. 2020 Sep;18(9):1257-1270. (PMID: 32503922)
J Clin Pathol. 2017 Mar;70(3):255-259. (PMID: 27531819)
Front Cell Dev Biol. 2020 Jul 08;8:605. (PMID: 32733895)
Oncologist. 2018 Apr;23(4):481-488. (PMID: 29330212)
Nat Rev Mol Cell Biol. 2012 Oct;13(10):673-9. (PMID: 22931853)
Int J Cancer. 2013 Apr 1;132(7):1487-95. (PMID: 22833228)
Breast J. 2019 Nov;25(6):1192-1197. (PMID: 31250492)
J Cell Biol. 2000 Feb 21;148(4):779-90. (PMID: 10684258)
Cancers (Basel). 2019 Jul 09;11(7):. (PMID: 31324031)
Sci Rep. 2021 Jan 8;11(1):82. (PMID: 33420229)
Dev Cell. 2006 Jul;11(1):93-104. (PMID: 16824956)
Clin Cancer Res. 2017 Jul 15;23(14):3859-3870. (PMID: 28153863)
Mol Cell Biol. 2007 Apr;27(8):3165-75. (PMID: 17296734)
J Clin Pathol. 2013 Mar;66(3):187-91. (PMID: 23112116)
BMC Cancer. 2009 Mar 03;9:74. (PMID: 19257890)
Cells. 2019 May 15;8(5):. (PMID: 31096701)
Mol Biosyst. 2008 Aug;4(8):835-50. (PMID: 18633485)
BMC Cancer. 2015 Feb 20;15:75. (PMID: 25881163)
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):E2595-604. (PMID: 22923691)
Tumour Biol. 2016 Jan;37(1):185-97. (PMID: 26602382)
J Cancer Res Clin Oncol. 2018 Aug;144(8):1401-1411. (PMID: 29923083)
Nat Cell Biol. 2010 Oct;12(10):982-92. (PMID: 20818389)
Biochim Biophys Acta. 1994 May 27;1198(1):11-26. (PMID: 8199193)
Clin Cancer Res. 2008 Jul 1;14(13):4038-44. (PMID: 18593979)
Breast J. 2020 Dec;26(12):2371-2375. (PMID: 32959535)
Cancer Lett. 2020 Jan 1;468:72-81. (PMID: 31605776)
Cancer Res. 2017 Aug 1;77(15):3982-3989. (PMID: 28428275)
PLoS One. 2019 Nov 6;14(11):e0224726. (PMID: 31693690)
Histol Histopathol. 2010 Aug;25(8):963-74. (PMID: 20552547)
Ann Surg Oncol. 2005 Jun;12(6):488-96. (PMID: 15864483)
Oncoimmunology. 2017 Jan 23;6(1):e1263412. (PMID: 28197390)
PLoS One. 2012;7(10):e47709. (PMID: 23112837)
Breast Cancer Res Treat. 2009 Sep;117(2):273-80. (PMID: 18815879)
Br J Cancer. 2020 Nov;123(11):1665-1672. (PMID: 32939056)
Mol Biol Cell. 2007 Sep;18(9):3533-44. (PMID: 17615296)
Cell Res. 2009 Feb;19(2):156-72. (PMID: 19153598)
Breast J. 2019 May;25(3):418-424. (PMID: 30925636)
EMBO J. 1999 Sep 15;18(18):5073-84. (PMID: 10487759)
Oncologist. 2018 Nov;23(11):1300-1309. (PMID: 30139837)
Neoplasia. 2018 Aug;20(8):775-788. (PMID: 29981499)
Curr Oncol Rep. 2015 Mar;17(3):431. (PMID: 25691085)
Mod Pathol. 2019 Jun;32(6):807-816. (PMID: 30723293)
J Clin Invest. 2011 Aug;121(8):3176-88. (PMID: 21747168)
Eur J Cancer. 2018 Jul;98:48-58. (PMID: 29870876)
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96. (PMID: 24556840)
Breast Cancer Res Treat. 2019 Jan;173(2):329-341. (PMID: 30341462)
Hum Pathol. 2019 Apr;86:85-92. (PMID: 30537493)
Oncotarget. 2017 Sep 7;8(48):83384-83406. (PMID: 29137351)
J Investig Dermatol Symp Proc. 1996 Apr;1(2):188-94. (PMID: 9627715)
Ann Oncol. 2012 Sep;23 Suppl 8:viii6-9. (PMID: 22918931)
World J Gastroenterol. 2016 Aug 7;22(29):6619-28. (PMID: 27547005)
Mod Pathol. 2018 Nov;31(11):1661-1674. (PMID: 29946183)
Dev Biol. 1995 May;169(1):347-58. (PMID: 7750650)
Oncogene. 2007 Nov 22;26(53):7445-56. (PMID: 17563753)
World J Surg Oncol. 2020 Jan 14;18(1):11. (PMID: 31937323)
PLoS One. 2008 Aug 06;3(8):e2888. (PMID: 18682804)
Prog Mol Biol Transl Sci. 2013;116:317-36. (PMID: 23481201)
Oncologist. 2021 Apr;26(4):e608-e621. (PMID: 33284507)
Virchows Arch. 2021 Apr;478(4):669-678. (PMID: 33089401)
Nat Cell Biol. 2009 Jun;11(6):694-704. (PMID: 19448627)
J Biol Chem. 1999 Jul 16;274(29):20489-98. (PMID: 10400677)
Breast Cancer Res Treat. 2012 Jan;131(1):41-8. (PMID: 21331622)
Am J Surg Pathol. 2017 Mar;41(3):334-342. (PMID: 28195880)
Mol Pathol. 1999 Jun;52(3):151-7. (PMID: 10621837)
BMC Cancer. 2019 Sep 5;19(1):881. (PMID: 31488082)
J Clin Med. 2019 May 09;8(5):. (PMID: 31075939)
Clin Breast Cancer. 2015 Apr;15(2):e105-15. (PMID: 25459069)
Breast Cancer Res Treat. 2020 Feb;180(1):87-95. (PMID: 31970558)
EMBO J. 2003 May 15;22(10):2453-62. (PMID: 12743039)
Cancer Res. 2009 May 15;69(10):4116-24. (PMID: 19435916)
Oncogene. 2017 Mar;36(11):1461-1473. (PMID: 27617575)
Am J Clin Pathol. 2016 Mar;145(3):365-72. (PMID: 27124919)
Cancer Res. 2011 Jun 1;71(11):3980-90. (PMID: 21502402)
Mod Pathol. 2001 Jul;14(7):650-4. (PMID: 11454996)
J Clin Pathol. 2019 Jun;72(6):418-424. (PMID: 30872384)
Nat Cell Biol. 2008 May;10(5):593-601. (PMID: 18376396)
Breast. 2019 Apr;44:29-32. (PMID: 30609392)
Int J Dev Biol. 2011;55(7-9):811-22. (PMID: 22161837)
Dev Biol. 1995 May;169(1):337-46. (PMID: 7750649)
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54. (PMID: 20713713)
J Biol Chem. 2008 May 30;283(22):14910-4. (PMID: 18411277)
J Pathol. 2019 Feb;247(2):214-227. (PMID: 30350370)
Mol Oncol. 2018 Sep;12(9):1540-1558. (PMID: 29741811)
Cancer Discov. 2021 May;11(5):1286-1305. (PMID: 33328216)
Curr Pharm Des. 2016;22(5):616-38. (PMID: 26825466)
Mod Pathol. 2012 Feb;25(2):178-84. (PMID: 22080057)
Mol Oncol. 2017 Jan;11(1):28-39. (PMID: 28085222)
J Clin Pathol. 2012 May;65(5):441-6. (PMID: 22412048)
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6392-7. (PMID: 18427106)
J Cancer. 2018 Jan 5;9(3):604-613. (PMID: 29483966)
Cancer Lett. 2017 Apr 28;392:83-93. (PMID: 28189533)
Diagn Pathol. 2010 Nov 26;5:76. (PMID: 21110878)
Arch Pathol Lab Med. 2015 May;139(5):642-9. (PMID: 25927147)
J Clin Med. 2015 Dec 25;5(1):. (PMID: 26712794)
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3264-9. (PMID: 21300877)
NPJ Breast Cancer. 2017 Dec 1;3:48. (PMID: 29214215)
Contributed Indexing:: Keywords: EMT; MBC; epithelial-mesenchymal transition immune system; metaplastic breast carcinoma
Substance Nomenclature:: 0 (B7-H1 Antigen)
0 (Biomarkers, Tumor)
0 (CD274 protein, human)
0 (Cadherins)
0 (MicroRNAs)
Entry Date(s):: Date Created: 20210724 Date Completed: 20210810 Latest Revision: 20210810
Update Code:: 20240105
PubMed Central ID:: PMC8306902
DOI:: 10.3390/ijms22147398
PMID:: 34299016
: Czasopismo naukowe

Pełny tekst

Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent triple negative (TN) invasive carcinomas with poor prognosis. MBCs have a different clinical behavior from other types of triple negative breast cancer (TNBC), being more resistant to standard chemotherapy. MBCs are an example of tumors with activation of epithelial-mesenchymal transition (EMT). The mechanisms involved in EMT could be responsible for the increase in the infiltrative and metastatic capacity of MBCs and resistance to treatments. In addition, a relationship between EMT and the immune response has been seen in these tumors. In this sense, MBC differ from other TN tumors showing a lower number of tumor-infiltrating lymphocytes (TILS) and a higher percentage of tumor cells expressing programmed death-ligand 1 (PD-L1). A better understanding of the relationship between the immune system and EMT could provide new therapeutic approaches in MBC.

Informacja